15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering PDS Biotechnology Corp, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $3.00 to $15.00 (about 5.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $9.00 sits 1207% above the current $0.69. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.12 next quarter toward $-0.47 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to PDS Biotechnology Corp.
As of Jul, 2 of 2 firms rate PDSB a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PDSB EPS & revenue forecast
EPS · NEXT QUARTER
$-0.12
Range $-0.15 – $-0.10 · 3 analysts · -39% YoY
Next period, 3 analysts expect PDS Biotechnology Corp to earn $-0.12 a share (range $-0.15 – $-0.10), versus $-0.19 a year earlier. Full-year consensus is $-0.50, growing to $-0.47 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering PDS Biotechnology Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PDSB.
#1
Mayank Mamtani
B. Riley Securities · Rank #9
Buy
$3.00+335.5% to target
Overall win rate
53%
+ Follow
#2
Joseph Pantginis
HC Wainwright & Co. · Rank #266
Buy
$15.00+2077.7% to target
Overall win rate
32%
+ Follow
#3
James Molloy
Alliance Global Partners · Rank #385
Buy
$4.50+553.3% to target
Overall win rate
25%
+ Follow
#4
KP
Kalpit Patel
B. Riley Securities
Buy
$3.00+335.5% to target
Coverage
—
+ Follow
PDSB stock forecast FAQ
What is PDSB's average 12-month price target?+
The 2 analysts with a live target average $9.00 for PDS Biotechnology Corp over the next 12 months, ranging from a $15.00 high to a $3.00 low.
Is PDSB stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for PDSB?+
The Street-high target is $15.00 (HC Wainwright & Co.), and the Street-low is $3.00 (B. Riley Securities). The average of all 2 active targets is $9.00.
How many Wall Street analysts cover PDSB?+
2 analysts have an active rating on PDS Biotechnology Corp, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering PDSB?+
Among analysts who currently cover PDSB, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #9). Their current call is Buy with a $3.00 target.
What is PDS Biotechnology Corp's projected EPS for next quarter?+
The consensus estimate is $-0.12 per share (range $-0.15 – $-0.10) across 3 analysts. Full-year EPS is projected at $-0.50, rising to $-0.47 the following year.
How much revenue is PDS Biotechnology Corp expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading PDSB lately?+
As of Jul, 2 of 2 firms rate PDSB a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PDSB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
